23 related articles for article (PubMed ID: 16675591)
21. Gefitinib inhibits the growth and invasion of urothelial carcinoma cell lines in which Akt and MAPK activation is dependent on constitutive epidermal growth factor receptor activation.
Nicolle G; Daher A; Maillé P; Vermey M; Loric S; Bakkar A; Wallerand H; Vordos D; Vacherot F; de Medina SG; Abbou CC; Van der Kwast T; Thiery JP; Radvanyi F; Chopin DK
Clin Cancer Res; 2006 May; 12(9):2937-43. PubMed ID: 16675591
[TBL] [Abstract][Full Text] [Related]
22. An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review).
Ferrer-Soler L; Vazquez-Martin A; Brunet J; Menendez JA; De Llorens R; Colomer R
Int J Mol Med; 2007 Jul; 20(1):3-10. PubMed ID: 17549382
[TBL] [Abstract][Full Text] [Related]
23. AURKA overexpression accompanies dysregulation of DNA-damage response genes in invasive urothelial cell carcinoma.
Veerakumarasivam A; Goldstein LD; Saeb-Parsy K; Scott HE; Warren A; Thorne NP; Mills IG; Venkitaraman A; Neal DE; Kelly JD
Cell Cycle; 2008 Nov; 7(22):3525-33. PubMed ID: 19001879
[TBL] [Abstract][Full Text] [Related]
[Previous] [New Search]
